Olaparib is a PARP inhibitor, which is already used to treat
certain ovarian cancer patients and prevents damaged cancer cells from repairing themselves after chemotherapy or radiotherapy.
Not exact matches
«For this reason, we decided to combine vitamin C with a PARP inhibitor, a drug type known to cause
cancer cell death by blocking the repair of DNA damage, and already approved for treating
certain patients with
ovarian cancer.»
Should the results be confirmed by further studies, it is possible that
patients with
certain genetic changes in BRCA1 could be identified as being at higher risk of breast and
ovarian cancer.
The drugs are already approved for treatment of
patients with advanced breast
cancer as well as
ovarian, pancreatic and
certain lung
cancers.